My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
January 2011
Top Stories
Updated IDSA Guideline on Fever and Neutropenia

An updated IDSA guideline for the use of antimicrobial agents in neutropenic cancer patients with fever is now available online. The guideline, previously updated in 2002, appears in the Feb. 15 issue of Clinical Infectious Diseases.

Recommendations provide guidance for clinicians treating cancer patients who develop either fever of unknown etiology or documented infections during chemotherapy-induced neutropenia. Recent improvements in antimicrobial drug development, diagnostic technology, and clinical management have led to a highly comprehensive, updated guideline. The document defines infection risk levels for neutropenic patients (high or low) based upon signs and symptoms present at the onset of fever, and outlines specific treatment algorithms for high- and low-risk patients.

In addition, the guideline indicates which patients are likely to benefit from antibiotic, antifungal, and antiviral prophylaxis. Also included is guidance regarding:  

  • defining characteristics of high-risk and low-risk patients with fever and neutropenia
  • what tests and cultures should be performed during the initial assessment
  • how antimicrobials should be modified during the course of fever and neutropenia
  • the duration of antibiotic prophylaxis and selection of agents

“Cancer patients with fever and neutropenia are not a uniform group who can all be managed in the same fashion,” said Alison Freifeld, MD, lead author of the guideline and professor of medicine at the University of Nebraska Medical Center in Omaha. “Our aim has been to bring some evidence-based order to the variabilities in presentation, infection source, and management approaches that clinicians are going to encounter.”

Information about the management of indwelling central venous catheters (CVCs) that become infected is a new addition to the guideline, as are recommended environmental precautions for neutropenic patients. Tables and figures also provide standards of management and empirical regimens for patients with fever and neutropenia. 

Important performance measures in the guideline include:

  • Patients with fever and neutropenia should be evaluated based on specific criteria (e.g., levels of risk, history, and physical examinations).
  • Antimicrobial changes to the empirical antibiotic regimen should be based on clinical, radiographic, or microbiological evidence of the infection.
  • Low-risk patients with an anticipated short duration of neutropenia (<7 days) do not require antibiotic prophylaxis. 

The guideline is available online and in a pocket-sized quick-reference format (see related IDSA News article). Other IDSA guidelines also are available on the Standards, Practice Guidelines, and Statements page of our website.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
CLSI Publishes New Breakpoints for Antimicrobial Susceptibility Testing
CDC Issues Guidance on Pre-Exposure Prophylaxis for HIV Prevention
Additional Practice Guidelines Now Available as Pocketcards
Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
PQRS and E-Prescribing Resources for ID Physicians
Physicians Excluded from FTC’s Identity Theft Rule
Global ID
New Report Calls for Expanded Use of Male Circumcision to Prevent HIV
Policy and Advocacy
FDA Releases Data on Antibiotic Use on the Farm
IDSA Continues to Weigh In on Consultation Codes
Your Colleagues
Members on the Move
Welcome, New Members!
Education & Resources
IDSA Influenza Conference Available Online, with CME Credit
New Fellowship in Transplant ID Available: 2011 Joint Research Awards
Online CME Available: Antimicrobial Stewardship in a Community Hospital
ABIM Foundation Grants Available for Medical Professionalism Efforts
Top Stories
From the President: The Intersection of Human and Animal Health
IDSA Releases Guideline for Treatment of MRSA Infections
Updated IDSA Guideline on Fever and Neutropenia
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.